IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Kenneth L. Arrington, et al. Applicants:

10/582,823 Serial No.

Filed: June 14, 2006

For: MITOTIC KINESIN INHIBITORS

Art Unit: To be determined

Examiner: To be determined

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.



INFORMATION DISCLOSURE STATEMENT

·=:)

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION					
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE				
э						
If this is inconvenient, additional copies will be submitted upon reques	st.					
6. In accordance with 37 C.F.R. 1.97, (check one)						
the attached information is filed within three months of the filing da	ate of the captioned case.					
the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the m	ailing of a first				
the attached information is filed before the mailing of a first Office examination under §1.114.	action after the filing of a re	equest for continued				
the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).						
each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.						
each item of information contained in the information disclosure sometimes from a foreign patent office in a counterpart application and this condesignated in §1.56(c) more than thirty days prior to the filing of the	ommunication was not rece	ived by any individual				
no item of information contained in this Information Disclosure State foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual desimonths prior to the filing of this Statement.	e knowledge of the person	signing the certification				
	Danis attallia salasittad					

Respectfully submitted,

By: David A. Muthard

Attorney For Applicant(s)

Reg. No. 35,297

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3903

Date: February 5, 2007

Su	ibstitute for form 1449A/PTO				COMPLETE IF KNOWN
I	NFORMATION 1	DIS	CLOSURE	Application Number	10/582,823
C.	TATEMENT BY	ADI	DIPE NT 6	Filing Date	June 14, 2006
3	IAIEMENI DI	Ar	/ 🗳	First Named Inventor	Kenneth L. Arrington
		!		Group Art Unit	To be determined
	(use as many sheets	as ne	ecossary)	Examiner Name	To be determined
Sheet	1	of	MEH	Attorney Docket Number	21439YP

			U.S. Pr	TENT DOCUMENTS		
Examiner Initials*	Cite No.	U.S. Patent Document Kind Code (if known		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		6,545,004		Finer, et al.	04/08/2003	
		3,463,778		Yale, et al.	08/26/1969	
		3,558,610		Breuer, et al.	01/26/1971	
		4,908,448		Aldag, et al.	03/13/1990	
		5,948,775		Koko, et al.	09/07/1999	
		3,231,572		Hayao, et al.	01/25/1965	
		3,257,397		Bolger, et al.	06/21/1966	
		2004/0116438		Lu, et al.	06/17/2004	
		5,925,642		Ulrich	07/20/1999	
				·		
	-					
			1			
			1			

	FOREIGN PATENT DOCUMENTS						
Foreign Patent Document					N. CD. A. V.	Date of Publication of	
Examiner Initials*	Cite No.	Office	Number .	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
		PCT	WO 03/062209		Neurogen Corporation	07/31/2003	
		PCT	WO 01/30768		Cytokinetics, Inc.	05/03/2001	
		PCT	WO 02/83143		Tularik, Inc.	10/24/2002	
		PCT	WO 01/19800		Curis, Inc.	03/22/2001	
		PCT	WO 04/039774		Merck & Co., Inc.	05/13/2004	
	-	РСТ	WO 03/103575		Cytokinetics, Inc.	12/18/2003	
		PCT	WO 2004/075863		Tularik, Inc.	09/10/2004	

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with Mary 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 09/30/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-06), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO			COMPLETE IF KNOWN				
	NFORMATION	DIS	CLOSURE	Ap	plication Number	10/582,823	
C!	FATEMENT BY	7 A TO	DIPE	Fili	ing Date	June 14, 2006	
3.	IAIEMENI BY	AP	1	1	st Named Inventor	Kenneth L. Arrington	_
	1		FER 1 2 2003	Ġħ.	up Art Unit	To be determined	_
	(use as many sheets	s as n	ecessary)	TX:	aminer Name	To be determined	
Sheet	2	of	2			21439YP	_

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
		Wagner, E., Acta Poloniae Pharmaceutica, Vol. 51 (4-5), pgs. 359-363 (1994)			
,		Bayoumy, B.E., et al. Polish Journal of Chemistry, Vol. 65 (7), pgs. 1265-1270 (1991)			
		Duhl, D.M., et al., Current Opinion in Drug Discovery & Development, Vol. 8, No. 4, pgs. 431-36 (2005)			
		Coleman, P.J., et al, Expert Opin. Ther. Patents, Vol. 14, No. 12, pgs. 1659-67 (2004)			
L					

Examiner	1	Date	
Signature	1	Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MF 2: 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.